

AVIVA PLC

Estate, GB-KY6 2SD Glenrothes; Tel: +44-1592 771241; Fax: +44-1592 771071; E-mail: ardmel@ardmel-group.co.uk; Inet: http://www.ardmel-group.co.uk; A: 1980; Eff: 175; Dev: GBP and Euro; Cap: 40.002000 (GBP); Act: Measuring and testing equipment; Decid: R. Fernando (Director General); Add: Manufacturers, Distributors.



ARRIVA PLC

Adr: Admiral Way, Doxford International Business Park, GB- Sunderland SR3 3XP; Tel: +44/(0)191/5204000; Fax: +44/(0)191/5204001; Inet: http://www.arriva.co.uk; A: 1997; Vat No: 176095050; Dev: £, Euro; Cap: 471.700.000 £; TO: 1.751.100.000 £; Act: Arriva is a leading European transport services organisation. With some 30.000 employees the Group provides transport services - including bus, rail, vehicle rental, water buses and demand responsive vehicles - in Denmark, Germany, Italy, the Netherlands, Portugal, Spain, Sweden and the UK.

Board of Directors: Sir Richard Broadbent (Non-Executive Chairman), Bob Davies (Chief Executive), David Martin (Group Managing Director - Operations & Deputy Chief Executive), Steve Clayton (Group Managing Director - Corporate Affairs), Steve Lonsdale (Group Managing Director - Finance), Michael Allen (Non-Executive Director), Simon Batey (Non-Executive Director), Veronica Palmer (Non-Executive Director).



ARTEMIDE GB LTD

Adr: 106 Great Russell Street, GB-WC1B 3N London; Tel: +44-20 7631 5200; Fax: +44-20 7631 5222; E-mail: info@artemide.co.uk; Inet: http://www.artemide.com; A: 1980; Eff: 15; Dev: GBP and Euro; Cap: 650000 (GBP); TO: 5234185; Act: Electrical and electronic equipment; Decid: M. Parker Chief Executive Officer; Add: Manufacturers.

ASSOCIATION OF INDEPENDENT RESEARCH & TECHNOLOGY ORGANISATIONS

Adr: GB-KT22 7YG Leatherhead; Tel: ++44/01372/802260; Fax: ++44/01372/802266; E-mail: airto@pira.co.uk; Eff: 5; Dev: £; TO: 132000; Act: International and national organisations. Public administration; Decid: B. Blunden (President).



AstraZeneca PLC

Adr: 15 Stanhope Gate, GB- London W1K 1LN; Tel: +44/(0)20/7304 5000; Fax: +44/(0)20/7304 5151; Inet: http://www.astrazeneca.com; A: 1999; Eff: 64.200; Dev: £, SEK, US\$, Euro; Cap: 14.418.000.000 US\$; TO: 16.456.500.000 *; Act: The principal activity of the group is the research, development, production and marketing of medicines for serious health conditions. The group's operation is focused on six therapy areas: Cardiovascular, Gastrointestinal, Neuroscience, Oncology, Respiratory and Inflammation and Infection. The group's key products include Atacand, Crestor, Exanta, Plendil, Seloken/Toprol-XL, Zestril, Losec/Prilosec, Nexium, Diprovan, Naropin, Seroquel, Xylocaine, Zomig, Arimidex, Casodex, Faslodex, Iressa, Nolvadex, Zoladex, Accolate, Oxis, Pulmicort, Rhinocort, Symbicort and Merrem/Meronem. The group operates in 27 manufacturing sites located in 19 countries. The group's geographic operations are located in the United Kingdom, Belgium, France, Germany, Italy, Spain, Sweden, the Netherlands, Canada, Puerto Rico, the United States of America, Australia and Japan; Decid: David Brennan (Board of Dir./CEO), Simon Lowth (Board of Dir./CFO), John Patterson (Board of Dir./Executive Dir.), Louis Schweitzer (Board of Dir./Non-Executive Chairman), Håkan Mogren (Board of Dir./Non-Executive Vice-Chairman); Bw: AstraZeneca UK Limited (UK), AstraZeneca Insurance Company Limited (UK), AstraZeneca Treasury Limited (UK), NV AstraZeneca SA (Belgium), AstraZeneca Dunkerque Production SCS (France), AstraZeneca SA (France), AstraZeneca GmbH (Germany), AstraZeneca Holding GmbH (Germany), AstraZeneca SpA (Italy), AstraZeneca Farmaceutica Spain SA (Spain), AstraZeneca AB (Sweden), AstraZeneca BV (The Netherlands), AstraZeneca Canada Inc. (Canada), IPR Pharmaceuticals Inc. (Puerto Rico), AstraZeneca LP (USA), AstraZeneca Pharmaceuticals LP (USA), Zeneca Holdings Inc. (USA), AstraZeneca Pty Limited (Australia), AstraZeneca KK (Japan).

AVIVA PLC

Adr: St Helen's, 1 Undershaft, GB- London EC3P